Kerzel et al., 2023 - Google Patents
In vivo macrophage engineering reshapes the tumor microenvironment leading to eradication of liver metastasesKerzel et al., 2023
View HTML- Document ID
- 9000816720800616366
- Author
- Kerzel T
- Giacca G
- Beretta S
- Bresesti C
- Notaro M
- Scotti G
- Balestrieri C
- Canu T
- Redegalli M
- Pedica F
- Genua M
- Ostuni R
- Kajaste-Rudnitski A
- Oshima M
- Tonon G
- Merelli I
- Aldrighetti L
- Dellabona P
- Coltella N
- Doglioni C
- Rancoita P
- Sanvito F
- Naldini L
- Squadrito M
- Publication year
- Publication venue
- Cancer cell
External Links
Snippet
Liver metastases are associated with poor response to current pharmacological treatments, including immunotherapy. We describe a lentiviral vector (LV) platform to selectively engineer liver macrophages, including Kupffer cells and tumor-associated macrophages …
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kerzel et al. | In vivo macrophage engineering reshapes the tumor microenvironment leading to eradication of liver metastases | |
| Chen et al. | CTLA-4 blockade induces a microglia-Th1 cell partnership that stimulates microglia phagocytosis and anti-tumor function in glioblastoma | |
| Marin et al. | Cellular senescence is immunogenic and promotes antitumor immunity | |
| Kerdidani et al. | Lung tumor MHCII immunity depends on in situ antigen presentation by fibroblasts | |
| De Simone et al. | Identification of a Kupffer cell subset capable of reverting the T cell dysfunction induced by hepatocellular priming | |
| Upadhyay et al. | A critical role for Fas-mediated off-target tumor killing in T-cell immunotherapy | |
| Dong et al. | Systematic immunotherapy target discovery using genome-scale in vivo CRISPR screens in CD8 T cells | |
| Li et al. | The transcription factor Bhlhe40 programs mitochondrial regulation of resident CD8+ T cell fitness and functionality | |
| Mohamed et al. | The unfolded protein response mediator PERK governs myeloid cell-driven immunosuppression in tumors through inhibition of STING signaling | |
| US11186825B2 (en) | Compositions and methods for evaluating and modulating immune responses by detecting and targeting POU2AF1 | |
| Zhang et al. | Knockdown of NEAT1 induces tolerogenic phenotype in dendritic cells by inhibiting activation of NLRP3 inflammasome | |
| Savage et al. | Amphiregulin from regulatory T cells promotes liver fibrosis and insulin resistance in non-alcoholic steatohepatitis | |
| EP3368689B1 (en) | Composition for modulating immune responses by use of immune cell gene signature | |
| US11180730B2 (en) | Compositions and methods for evaluating and modulating immune responses by detecting and targeting GATA3 | |
| Chen et al. | Circular RNA circSnx5 controls immunogenicity of dendritic cells through the miR-544/SOCS1 axis and PU. 1 activity regulation | |
| Jamison et al. | Nanoparticles containing an insulin–ChgA hybrid peptide protect from transfer of autoimmune diabetes by shifting the balance between effector T cells and regulatory T cells | |
| US20190262399A1 (en) | Compositions and methods for evaluating and modulating immune responses | |
| Isshiki et al. | EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function | |
| Tsuchiya et al. | Type I interferon delivery by iPSC-derived myeloid cells elicits antitumor immunity via XCR1+ dendritic cells | |
| AU2018244371A1 (en) | Methods of isolating neoantigen-specific T cell receptor sequences | |
| Aldhamen et al. | Endoplasmic reticulum aminopeptidase-1 functions regulate key aspects of the innate immune response | |
| Lelliott et al. | NKG7 enhances CD8+ T cell synapse efficiency to limit inflammation | |
| Kim et al. | Hybrid Fc‐fused interleukin‐7 induces an inflamed tumor microenvironment and improves the efficacy of cancer immunotherapy | |
| Schreiber et al. | Impact of TCR diversity on the development of transplanted or chemically induced tumors | |
| Kerdidani et al. | Cigarette smoke–induced emphysema exhausts early cytotoxic CD8+ T cell responses against nascent lung cancer cells |